Changing paradigms in the systemic treatment of advanced cervical cancer

American Journal of Obstetrics and Gynecology

Volumn 214, Issue 1, 2016, Pages 22-30

  Pfaendler, Krista S ^a   Tewari, Krishnansu S ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

antiangiogenesis; bevacizumab; cervical cancer

Indexed keywords

ANGIOGENESIS INHIBITOR; ANTINEOPLASTIC AGENT; BEVACIZUMAB;

FEMALE; HUMAN; METASTASIS; PATHOLOGY; TUMOR RECURRENCE; UTERINE CERVICAL NEOPLASMS;

ANGIOGENESIS INHIBITORS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BEVACIZUMAB; FEMALE; HUMANS; NEOPLASM METASTASIS; NEOPLASM RECURRENCE, LOCAL; UTERINE CERVICAL NEOPLASMS;

EID: 84955742760     PISSN: 00029378     EISSN: 10976868     Source Type: Journal    
DOI: 10.1016/j.ajog.2015.07.022     Document Type: Review

References (42)

1. Ferlay J, Soerjomataram I, Ervik M, et al. GLOBOCAN 2012 v1.0, Cancer incidence and mortality worldwide: IARC CancerBase No. 11(Internet). 2013. Available at: http://globocan.iarc.fr. Accessed April 8, 2015.
2. R.L. Siegel, K.D. Miller, and A. Jemal Cancer statistics, 2015 CA Cancer J Clin 65 2015 5 29
3. P.L. McCormack Quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine (Gardasil): a review of its use in the prevention of premalignant anogenital lesions, cervical and anal cancers, and genital warts Drugs 74 2014 1253 1283
4. J.M. Walboomers, M.V. Jacobs, M.M. Manos, and et al. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide J Pathol 189 1999 12 19
5. H. Zur Hausen, and E.M. de Villiers Human papillomaviruses Ann Rev Microbiol 48 1994 427 447
6. American College of Obstetricians and Gynecologists Screening for cervical cancer. ACOG Practice Bulletin no. 131 Obstet Gynecol 120 2012 1222 1238
7. E.A. Joura, S.K. Kjaer, C.M. Wheeler, and et al. HPV antibody levels and clinical efficacy following administration of a prophylactic quadrivalent HPV vaccine Vaccine 26 2008 6844 6851
8. T. Malagon, M. Drolet, M.C. Boily, and et al. Cross-protective efficacy of two human papillomavirus vaccines: a systematic review and meta-analysis Lancet Infect Dis 12 2012 781 789
9. L.E. Markowitz, E.F. Dunne, M. Saraiya, and et al. Human papillomavirus vaccination: recommendations of the Advisory Committee on Immunization Practices (ACIP) MMWR Recomm Rep 63 2014 1 30 Erratum in: MMWR Recomm Rep 2014;63:1182
10. Centers for Disease Control and Prevention. 2013 NIS-Teen Vaccination Coverage Table Data. 2014. Available at: http://www.cdc.gov/vaccines/imz-managers/coverage/nis/teen/data/tables-2013.html. Accessed Nov. 11, 2014.
11. A. Subramaniam, J.M. Fauci, K.E. Schneider, and et al. Invasive cervical cancer and screening: what are the rates of unscreened and underscreened women in the modern era? J Low Genit Tract Dis 15 2011 110 113
12. S.E. Waggoner Cervical cancer Lancet 361 2003 2217 2225
13. Howlader N, Noone AM, Krapcho M, et al. SEER Cancer Statistics Review, 1975-2012, National Cancer Institute. Bethesda, MD. Available at: www.seer.cancer.gov. Accessed April 1, 2015.
14. T. Thigpen, H. Shingleton, H. Homesley, L. LaGasse, and J. Blessing Cis-dichlorodiammineplatinum(II) in the treatment of gynecologic malignancies: phase II trials by the Gynecologic Oncology Group Cancer Treat Rep 63 1979 1549 1555
15. D.H. Moore, J.A. Blessing, R.P. McQuellon, and et al. Phase III study of cisplatin with or without paclitaxel in stage IVB, recurrent, or persistent squamous cell carcinoma of the cervix: a Gynecologic Oncology Group study J Clin Oncol 22 2004 3113 3119
16. H.J. Long 3rd, B.N. Bundy, E.C. Grendys Jr., and et al. Randomized phase III trial of cisplatin with or without topotecan in carcinoma of the uterine cervix: a Gynecologic Oncology Group study J Clin Oncol 23 2005 4626 4633
17. B.J. Monk, M.W. Sill, D.S. McMeekin, and et al. Phase III trial of four cisplatin-containing doublet combinations in stage IVB, recurrent, or persistent cervical carcinoma: a Gynecologic Oncology Group study J Clin Oncol 27 2009 4649 4655
18. D.H. Moore, C. Tian, B.J. Monk, H.J. Long, G.A. Omura, and J.D. Bloss Prognostic factors for response to cisplatin-based chemotherapy in advanced cervical carcinoma: a Gynecologic Oncology Group study Gynecol Oncol 116 2010 44 49
19. I. Saito, R. Kitagawa, H. Fukuda, and et al. A phase III trial of paclitaxel plus carboplatin versus paclitaxel plus cisplatin in stage IVB, persistent or recurrent cervical cancer: Gynecologic Cancer Study Group/Japan Clinical Oncology Group Study (JCOG0505) Jpn J Clin Oncol 40 2010 90 93
20. R. Kitagawa, N. Katsumata, T. Shibata, and et al. Paclitaxel plus carboplatin versus paclitaxel plus cisplatin in metastatic or recurrent cervical cancer: The Open-Label Randomized Phase III Trial JCOG0505 J Clin Oncol 33 2015 2129 2135
21. J.D. Bloss, J.A. Blessing, B.C. Behrens, and et al. Randomized trial of cisplatin and ifosfamide with or without bleomycin in squamous carcinoma of the cervix: a Gynecologic Oncology Group study J Clin Oncol 20 2002 1832 1837
22. G.A. Omura, J.A. Blessing, L. Vaccarello, and et al. Randomized trial of cisplatin versus cisplatin plus mitolactol versus cisplatin plus ifosfamide in advanced squamous carcinoma of the cervix: a Gynecologic Oncology Group study J Clin Oncol 15 1997 165 171
23. R.S. Kerbel Tumor angiogenesis N Engl J Med 358 2008 2039 2049
24. N. Ferrara, K.J. Hillan, H.P. Gerber, and W. Novotny Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer Nature Rev Drug Discov 3 2004 391 400
25. J.D. Wright, D. Viviano, M.A. Powell, and et al. Bevacizumab combination therapy in heavily pretreated, recurrent cervical cancer Gynecol Oncol 103 2006 489 493
26. B.J. Monk, M.W. Sill, R.A. Burger, H.J. Gray, T.E. Buekers, and L.D. Roman Phase II trial of bevacizumab in the treatment of persistent or recurrent squamous cell carcinoma of the cervix: a Gynecologic Oncology Group study J Clin Oncol 27 2009 1069 1074
27. T.E. Schefter, K. Winter, J.S. Kwon, and et al. A phase II study of bevacizumab in combination with definitive radiotherapy and cisplatin chemotherapy in untreated patients with locally advanced cervical carcinoma: preliminary results of RTOG 0417 Int J Radiat Oncol Biol Phys 83 2012 1179 1184
28. T. Schefter, K. Winter, J.S. Kwon, and et al. RTOG 0417: efficacy of bevacizumab in combination with definitive radiation therapy and cisplatin chemotherapy in untreated patients with locally advanced cervical carcinoma Int J Radiat Oncol Biol Phys 88 2014 101 105
29. I. Zighelboim, J.D. Wright, F. Gao, and et al. Multicenter phase II trial of topotecan, cisplatin and bevacizumab for recurrent or persistent cervical cancer Gynecol Oncol 130 2013 64 68
30. K.S. Tewari, M.W. Sill, H.J. Long 3rd, and et al. Improved survival with bevacizumab in advanced cervical cancer N Engl J Med 370 2014 734 743
31. K.S. Tewari, M.W. Sill, R.T. Penson, and et al. Final overall survival analysis of the phase III randomized trial of chemotherapy with and without bevacizumab for advanced cervical cancer: a NRG Oncology-Gynecologic Oncology Group study Sept. 28, 2014 Proffered Paper Session presented at European Society for Medical Oncology Madrid, Spain
32. K.S. Tewari, M.W. SIll, B.J. Monk, and et al. Prospective validation of pooled prognostic factors in women with advanced cervical cancer treated with chemotherapy with and without bevacizumab: a NRG Oncology/Gynecologic Oncology Group Study Clin Cancer Res 2015 (In press)
33. L.Q. Chow, and S.G. Eckhardt Sunitinib: from rational design to clinical efficacy J Clin Oncol 25 2007 884 896
34. H.J. Mackay, A. Tinker, E. Winquist, and et al. A phase II study of sunitinib in patients with locally advanced or metastatic cervical carcinoma: NCIC CTG Trial IND.184 Gynecol Oncol 116 2010 163 167
35. B.J. Monk, L. Mas Lopez, J.J. Zarba, and et al. Phase II, open-label study of pazopanib or lapatinib monotherapy compared with pazopanib plus lapatinib combination therapy in patients with advanced and recurrent cervical cancer J Clin Oncol 28 2010 3562 3569
36. B.J. Monk, and L.N. Pandite Survival data from a phase II, open-label study of pazopanib or lapatinib monotherapy in patients with advanced and recurrent cervical cancer J Clin Oncol 29 2011 4845
37. R.P. Symonds, C. Gourley, S. Davidson, and et al. Cediranib combined with carboplatin and paclitaxel in patients with metastatic or recurrent cervix cancer (CIRCCa): a randomised, double blind, placebo-controlled phase 2 trial Lancet Oncol 2015 (In press)
38. K.S. Tewari, and B.J. Monk Invasive cervical cancer P.J. DiSaia, W.T. Creasman, Clinical gynecologic oncology: expert consult 8th ed. 2012 Elsevier Health Sciences Philadelphia, PA 51 120
39. H.J. Yoo, M.C. Lim, S.S. Seo, and et al. Pelvic exenteration for recurrent cervical cancer: ten-year experience at National Cancer Center in Korea J Gynecol Oncol 23 2012 242 250
40. L.E. Minion, J. Bai, B.J. Monk, and et al. A Markov model to evaluate cost-effectiveness of antiangiogenesis therapy using bevacizumab in advanced cervical cancer Gynecol Oncol 137 2015 490 496
41. R. Feldman, Z. Gatalica, S.K. Reddy, and K.S. Tewari Paving the road to personalized medicine in cervical cancer: Theranostic biomarker evaluation in a 592-specimen library Gynecol Oncol 137 suppl1 2015 141
42. Tewari KS, Sill MW, Penson RT, et al. Impact of circulating tumor cells (CTCs) on overall survival among patients treated with chemotherapy plus bevacizumab for advanced cervical cancer: a NRG Oncology - Gynecologic Oncology Group study. Presented at the Society of Gynecologic Oncology, Chicago, IL, March 29, 2015.